Literature DB >> 29801103

Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study.

Miki Horiguchi1, Lu Tian2, Hajime Uno3, SuChun Cheng4, Dae Hyun Kim5, Deb Schrag3, Lee-Jen Wei6.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29801103      PMCID： PMC6145678          DOI： 10.1001/jamaoncol.2018.0518

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Authors:  Alan P Venook; Donna Niedzwiecki; Heinz-Josef Lenz; Federico Innocenti; Briant Fruth; Jeffrey A Meyerhardt; Deborah Schrag; Claire Greene; Bert H O'Neil; James Norman Atkins; Scott Berry; Blase N Polite; Eileen M O'Reilly; Richard M Goldberg; Howard S Hochster; Richard L Schilsky; Monica M Bertagnolli; Anthony B El-Khoueiry; Peter Watson; Al B Benson; Daniel L Mulkerin; Robert J Mayer; Charles Blanke
Journal:  JAMA       Date:  2017-06-20       Impact factor: 56.272

2.  A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies.

Authors:  Junlong Li; Lihui Zhao; Lu Tian; Tianxi Cai; Brian Claggett; Andrea Callegaro; Benjamin Dizier; Bart Spiessens; Fernando Ulloa-Montoya; Lee-Jen Wei
Journal:  Biometrics       Date:  2015-12-21       Impact factor: 2.571

3.  Designing therapeutic cancer vaccine trials with delayed treatment effect.

Authors:  Zhenzhen Xu; Boguang Zhen; Yongsoek Park; Bin Zhu
Journal:  Stat Med       Date:  2016-11-02       Impact factor: 2.373

4.  Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.

Authors:  Lihui Zhao; Lu Tian; Hajime Uno; Scott D Solomon; Marc A Pfeffer; Jerald S Schindler; Lee Jen Wei
Journal:  Clin Trials       Date:  2012-08-22       Impact factor: 2.486

5.  Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.

Authors:  Kyongsun Pak; Hajime Uno; Dae Hyun Kim; Lu Tian; Robert C Kane; Masahiro Takeuchi; Haoda Fu; Brian Claggett; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

6.  Statistical issues and challenges in immuno-oncology.

Authors:  Tai-Tsang Chen
Journal:  J Immunother Cancer       Date:  2013-10-21       Impact factor: 13.751
  6 in total
  2 in total

1.  Statistical Considerations for Sequential Analysis of the Restricted Mean Survival Time for Randomized Clinical Trials.

Authors:  Ying Lu; Lu Tian
Journal:  Stat Biopharm Res       Date:  2020-10-09       Impact factor: 1.452

2.  Correlation between tumor location and survival in stage I lung adenocarcinoma and squamous cell carcinoma: a SEER-based study.

Authors:  Junjie Hu; Mengfan Qi; Xinsheng Zhu; Yan Chen; Jie Dai; Jing Zhang; Gening Jiang; Zhonghong Zhang; Peng Zhang
Journal:  J Cancer       Date:  2021-06-22       Impact factor: 4.207
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.